---
figid: PMC10948527__fimmu-15-1340726-g004
figtitle: Immune cell-specific roles of SHP2
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10948527
filename: PMC10948527__fimmu-15-1340726-g004.jpg
figlink: /pmc/articles/PMC10948527/figure/F4
number: F4
caption: 'Immune cell-specific roles of SHP2. (A) SHP2 in T lymphocytes. SHP2 is recruited
  by various immunosuppressive receptors like PD-1, CTLA-4, BTLA, TIGIT, etc. The
  immunosuppressive effects of SHP2 via PD-1 involve (1): direct inhibition of the
  PI3K-AKT signaling pathway (2); dephosphorylation of ZAP70, indirect inhibition
  of PI3K-AKT and RAS-ERK pathways (3); dephosphorylation of CD28 to indirectly inhibit
  the PI3K-AKT pathway (4); For CTLA-4, cytoplasmic SHP2 antagonizes CD28 positive
  signals, playing a tumor-promoting role (5); PD-1 disrupts CD226 activation through
  distinct mechanisms when converging with TIGIT (6); SHP2 dephosphorylates ITK downstream
  of PD-1, inhibiting T cell function. Downstream signaling of SHP2 recruited by BTLA
  remains unclear. (B) SHP2 in myeloid cells/macrophages. SHP2 promotes tumor growth
  via TAMs through (1): binding to CSF-1-induced signaling complexes, enhancing macrophage
  proliferation and M2 polarization under CSF-1 stimulation (2); recruiting SIRPα
  or Siglec-10 receptors to reduce phagocytosis upon CD47 or CD24 stimulation (3);
  promoting macrophage proliferation via a macrophage/CXCL9-Th1 cell/IFN-γ feedback
  loop (4); dephosphorylating STAT downstream of IL-10 signaling, inhibiting anti-inflammatory
  factors, and exacerbating colitis-related colon cancer (5); attenuating GM-CSF-mediated
  phosphorylation of HOXA10 and IRF8'
papertitle: Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted
  therapy?
reftext: Xun Chen, et al. Front Immunol. 2024;15(NA).
year: '2024'
doi: 10.3389/fimmu.2024.1340726
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media S.A.
keywords: SHP2 | solid tumor | signaling pathway | tumor microenvironment | immune
  microenvironment | therapy resistance
automl_pathway: 0.954816
figid_alias: PMC10948527__F4
figtype: Figure
redirect_from: /figures/PMC10948527__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10948527__fimmu-15-1340726-g004.html
  '@type': Dataset
  description: 'Immune cell-specific roles of SHP2. (A) SHP2 in T lymphocytes. SHP2
    is recruited by various immunosuppressive receptors like PD-1, CTLA-4, BTLA, TIGIT,
    etc. The immunosuppressive effects of SHP2 via PD-1 involve (1): direct inhibition
    of the PI3K-AKT signaling pathway (2); dephosphorylation of ZAP70, indirect inhibition
    of PI3K-AKT and RAS-ERK pathways (3); dephosphorylation of CD28 to indirectly
    inhibit the PI3K-AKT pathway (4); For CTLA-4, cytoplasmic SHP2 antagonizes CD28
    positive signals, playing a tumor-promoting role (5); PD-1 disrupts CD226 activation
    through distinct mechanisms when converging with TIGIT (6); SHP2 dephosphorylates
    ITK downstream of PD-1, inhibiting T cell function. Downstream signaling of SHP2
    recruited by BTLA remains unclear. (B) SHP2 in myeloid cells/macrophages. SHP2
    promotes tumor growth via TAMs through (1): binding to CSF-1-induced signaling
    complexes, enhancing macrophage proliferation and M2 polarization under CSF-1
    stimulation (2); recruiting SIRPα or Siglec-10 receptors to reduce phagocytosis
    upon CD47 or CD24 stimulation (3); promoting macrophage proliferation via a macrophage/CXCL9-Th1
    cell/IFN-γ feedback loop (4); dephosphorylating STAT downstream of IL-10 signaling,
    inhibiting anti-inflammatory factors, and exacerbating colitis-related colon cancer
    (5); attenuating GM-CSF-mediated phosphorylation of HOXA10 and IRF8'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KRAS
  - HRAS
  - NRAS
  - PTPN11
  - CD274
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - BTLA
  - CTLA4
  - CD28
  - TNFRSF14
  - ZAP70
  - PVR
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - ITK
  - EPHB2
  - MAPK1
  - MAPK3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - CD226
  - AKT1
  - AKT2
  - AKT3
  - TIGIT
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - CD47
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - NFKB1
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - MTOR
  - SIRPA
  - CXCL9
  - APC
  - PROC
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - CD24
  - SIGLEC10
  - IRF8
  - HOXA10
  - IFNG
  - CSF1R
  - IL10
  - CSF1
  - RAS
  - PD1
  - MEK
  - CXCL9
---
